Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07729956 PD-1 monoclonal antibody(Sichuan Baili Pharmaceutical) Triple Negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07729956 clinical trial report covering PD-1 monoclonal antibody(Sichuan Baili Pharmaceutical), Phase 3, endpoints, sponsor, geography, readout timing a
Latest Hotspot
8 min read
CTR20262703 Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influ Influenza B virus infection Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
CTR20262703 clinical trial report covering Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influ, Phase 3, endpoints, sponsor, g
Latest Hotspot
8 min read
NCT07730489 Trastuzumab Brengitecan Colorectal Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07730489 clinical trial report covering Trastuzumab Brengitecan, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600129030 Anlotinib Dihydrochloride Advanced Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
ChiCTR2600129030 clinical trial report covering Anlotinib Dihydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white spa
Latest Hotspot
8 min read
JPRN-jRCT2031260346 Bevacizumab-awwb Platinum-Sensitive Ovarian Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
JPRN-jRCT2031260346 clinical trial report covering Bevacizumab-awwb, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07730840 Zastaprazan citrate Ischemic Attack, Transient Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07730840 clinical trial report covering Zastaprazan citrate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07730138 Fexuprazan hydrochloride Stomach Ulcer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07730138 clinical trial report covering Fexuprazan hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262771 Qinqiao Yanshu Granules Acute pharyngitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
CTR20262771 clinical trial report covering Qinqiao Yanshu Granules, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
Lexatumumab Biologics Sequence Review Report 2026: TNFRSF10B Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lexatumumab, an antibody targeting TNFRSF10B.
Latest Hotspot
8 min read
Tenatumomab Biologics Sequence Review Report 2026: TNC Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tenatumomab, an antibody targeting TNC.
Latest Hotspot
8 min read
Figitumumab Biologics Sequence Review Report 2026: IGF-1R Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Figitumumab, an antibody targeting IGF-1R.
Latest Hotspot
8 min read
Citatuzumab Biologics Sequence Review Report 2026: EPCAM Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Citatuzumab, an antibody targeting EPCAM.